Roche's (OTCQX:RHHBY +0.5%) Ventana Medical Systems enters into an agreement with ImmunoGen (IMGN +2.2%) to develop biomarker assays and a companion immunohistochemistry diagnostic test for one or more of ImmunoGen's product candidates. The initial test in the partnership is for folate receptor alpha (FRa) that is being used in the trials of ImmunoGen's FRa-targeting antibody-drug conjugate, IMGN853. Certain cancers such as epithelial ovarian and endometrial, highly express FRa.
Specific financial terms are not disclosed.
Subscribe for full text news in your inbox